TABLE 2.

Scenarios of Chlamydia Screening and PN in the United States Included in the Study

Scenario Name	Screening	PN
1. 2000–2015
Current policy	Screening coverage as estimated in the model*	PN uptake as estimated in the model†
No screening and no PN	No screening, but people with symptomatic infection can be tested and treated	No PN‡
2.1. 2016–2019
Guidelines	Annual screening of all sexually active women aged 15–24 y§	PN uptake estimated in the model†
Current policy	Screening coverage as estimated in the model in 2015*	PN uptake as estimated in the model†
2.2. 2016–2019 + 5 y (2020–2024)
Guidelines	For 2016–2019: 100% screening coverage (annual) of all sexually-active women aged 15–24 y§ For 2020–2024: Screening coverage estimated in the model in 2015*	PN uptake as estimated in the model†
Current policy	Screening coverage as of 2015 estimated in the model*	PN uptake as estimated in the model†

In scenario 1, the reference strategy is “no screening & no PN”. In scenarios 2.1 and 2.2, the reference strategy is “current policy”.

*Screening coverage for 2000–2015 was as estimated in the calibrated model.² For scenarios 2.1 and 2.2, screening uptake in year 2016 and beyond was assumed to be the same as the calibrated model estimate for 2015.

^†PN uptake for 2000–2015 was as estimated in the calibrated model.² For scenarios 2.1 and 2.2, PN uptake in year 2016 and beyond was assumed to be the same as the calibrated model estimate for 2015.

^‡In the “no PN” scenario, physician-initiated PN is set to 0, but patient-initiated PN is retained.

^§In the annual screening coverage scenario, all sexually-active women aged 15–24 years are screened annually, and screening coverage of women aged 25 years and over is the same as in the “current policy” scenario.